Effect of haemodialysis on the pharmacokinetics of cetirizine
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The pharmacokinetics of Cetirizine, a histamine H1-receptor antagonist, were investigated in five renal failure patients undergoing chronic haemodialysis therapy. The patients received one 10 mg cetirizine dihydrochloride capsule 3 h before haemodialysis.
Concentrations of cetirizine in serum and dialysate were determined by HPLC. The maximum serum cetirizine concentration and the time to reach that maximum were 285 μg·1−1 and 2.0 h, respectively. The terminal disposition half-life of cetirizine in these patients was 19.3 h.
The haemodialysis clearance of cetirizine was 14.0 ml · min−1. Although this is approximately 33% of the apparent total body clearance of cetirizine in subjects with normal renal function, the fraction of the dose removed by dialysis was only 9.4%. Thus, since haemodialysis does not produce a clinically significantly alteration in cetirizine elimination, no supplemental dose should be necessary after dialysis.
- Maddox, DE, Reed, CE (1987) Clinical pharmacodynamics of antihistamines. Ann Allergy 59: pp. 43-48
- Snyder, SH, Snowman, AM (1987) Receptor effects of cetirizine. Ann Allergy 59: pp. 4-8
- Simons, FE, Simons, KJ, Chung, M, Yeh, J (1987) The comparative pharmacokinetics of H1-receptor antagonists. Ann Allergy 59: pp. 20-24
- Matzke, GR, Yeh, J, Awni, WM, Halstenson, CE, Chung, M (1987) Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy 59: pp. 25-30
- Wood, SG, John, BA, Chasseaud, LF, Yeh, J, Chung, M (1987) The metabolism and pharmacokinetics of 14C-Cetirizine in humans. Ann Allergy 59: pp. 31-34
- Effect of haemodialysis on the pharmacokinetics of cetirizine
European Journal of Clinical Pharmacology
Volume 38, Issue 1 , pp 67-69
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- renal failure
- Industry Sectors
- Author Affiliations
- 1. The Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota, U.S.A.
- 2. College of Pharmacy and School of Medicine, University of Minnesota, Minneapolis, Minnesota, U.S.A.
- 3. Pfizer Pharmaceuticals, New York, New York, U.S.A.